Patents by Inventor Katherine Mace
Katherine Mace has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10076131Abstract: The present invention generally relates to the field of nutrition. In particular the present invention relates to infant nutrition in the post natal period and in early life, more particular during the age period of 6-36 months or during a part thereof. One embodiment of the present invention is a kit of diet compositions for children during the age period of 6-36 months or during a part thereof, wherein the macronutrient content of the compositions is gradually changing in the form of a straight line from a composition that comprises about 40-50% energy from fat and about 40-49% energy from carbohydrates for children at the age of 6 months to a composition that comprises about 30-35% energy from fat and about 50-55% energy from carbohydrates for children at the age of 36 months, and its use to prevent obesity later in life.Type: GrantFiled: June 27, 2016Date of Patent: September 18, 2018Assignee: Nestec S.A.Inventors: Yasaman Shahkhalili, Kevin Acheson, Katherine Mace, Julie Moulin, Irene Zbinden, Olivier Aprikian, Theresa Voss
-
Publication number: 20160374384Abstract: The present invention generally relates to the field of nutrition. In particular the present invention relates to infant nutrition in the post natal period and in early life, more particular during the age period of 6-36 months or during a part thereof. One embodiment of the present invention is a kit of diet compositions for children during the age period of 6-36 months or during a part thereof, wherein the macronutrient content of the compositions is gradually changing in the form of a straight line from a composition that comprises about 40-50% energy from fat and about 40-49% energy from carbohydrates for children at the age of 6 months to a composition that comprises about 30-35% energy from fat and about 50-55% energy from carbohydrates for children at the age of 36 months, and its use to prevent obesity later in life.Type: ApplicationFiled: June 27, 2016Publication date: December 29, 2016Inventors: Yasaman Shahkhalili, Kevin Acheson, Katherine Mace, Julie Moulin, Irene Zbinden, Olivier Aprikian, Theresa Voss
-
Patent number: 9402412Abstract: The present invention generally relates to the field of nutrition. In particular the present invention relates to infant nutrition in the post natal period and in early life, more particular during the age period of 6-36 months or during a part thereof. One embodiment of the present invention is a kit of diet compositions for children during the age period of 6-36 months or during a part thereof, wherein the macronutrient content of the compositions is gradually changing in the form of a straight line from a composition that comprises about 40-50% energy from fat and about 40-49% energy from carbohydrates for children at the age of 6 months to a composition that comprises about 30-35% energy from fat and about 50-55% energy from carbohydrates for children at the age of 36 months, and its use to prevent obesity later in life.Type: GrantFiled: May 30, 2007Date of Patent: August 2, 2016Assignee: Nestec S.A.Inventors: Yasaman Shahkhalili, Kevin Acheson, Katherine Mace, Julie Moulin, Irene Zbinden, Olivier Aprikian, Theresa Voss
-
Patent number: 8710003Abstract: A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.Type: GrantFiled: May 18, 2010Date of Patent: April 29, 2014Assignee: Nestec S.A.Inventors: Raylene Alison Reimer, Christian Darimont-Nicolau, Katherine Mace, Sandrine Gremlich, Jean-Richard Neeser
-
Publication number: 20100297253Abstract: A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.Type: ApplicationFiled: May 18, 2010Publication date: November 25, 2010Inventors: Raylene Alison REIMER, Christian Darimont-Nicolau, Katherine Mace, Sandrine Gremlich, Jean-Richard Neeser
-
Publication number: 20100255114Abstract: The present invention generally relates to the field of nutrition. In particular the present invention relates to infant nutrition in the post natal period and in early life, more particular during the age period of 6-36 months or during a part thereof One embodiment of the present invention is a kit of diet compositions for children during the age period of 6-36 months or during a part thereof, wherein the macronutrient content of the compositions is gradually changing in the form of a straight line from a composition that comprises about 40-50% energy from fat and about 40-49% energy from carbohydrates for children at the age of 6 months to a composition that comprises about 30-35% energy from fat and about 50-55% energy from carbohydrates for children at the age of 36 months, and its use to prevent obesity later in life.Type: ApplicationFiled: May 30, 2008Publication date: October 7, 2010Inventors: Yasaman Shahkhalili, Kevin Acheson, Katherine Mace, Julie Moulin, Irene Zeinden, Olivier Aprikian, Theresa Voss, Silja Ursel, Martinas Kuslys
-
Patent number: 7585618Abstract: A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.Type: GrantFiled: April 19, 2005Date of Patent: September 8, 2009Assignee: Nestec S.A.Inventors: Raylene Reimer, Christian Darimont-Nicolau, Katherine Mace, Sandrine Gremlich, Jean-Richard Neeser
-
Publication number: 20080300195Abstract: The present invention generally relates to the field of nutrition. In particular the present invention relates to infant nutrition in the post natal period and in early life, more particular during the age period of 6-36 months or during a part thereof. One embodiment of the present invention is a kit of diet compositions for children during the age period of 6-36 months or during a part thereof, wherein the macronutrient content of the compositions is gradually changing in the form of a straight line from a composition that comprises about 40-50% energy from fat and about 40-49% energy from carbohydrates for children at the age of 6 months to a composition that comprises about 30-35% energy from fat and about 50-55% energy from carbohydrates for children at the age of 36 months, and its use to prevent obesity later in life.Type: ApplicationFiled: May 30, 2007Publication date: December 4, 2008Applicant: NESTEC S.A.Inventors: Yasaman Shahkhalili, Kevin Acheson, Katherine Mace, Julie Moulin, Irene Zbinden, Olivier Aprikian, Theresa Voss
-
Patent number: 7294509Abstract: This invention relates to new immortalized human pre-adipose cell lines capable of differentiating into adipose cells and methods of obtaing the immortalized cells. In particular, the present invention pertains to immortalized pre-adipocyte cell lines derived from white adipose tissue and methods of producing the cell lines. The immortalized pre-adipocyte cells are capable of maturing into immortalized white adipose cells useful in developing drugs, food ingredients and supplements against obesity, diabetes and cardiovascular diseases.Type: GrantFiled: January 21, 2003Date of Patent: November 13, 2007Assignee: Nestec S.A.Inventors: Christian Darimont, Katherine Mace, Andrea Pfeifer
-
Publication number: 20050186558Abstract: A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.Type: ApplicationFiled: April 19, 2005Publication date: August 25, 2005Inventors: Raylene Reimer, Christian Darimont-Nicolau, Katherine Mace, Sandrine Gremlich, Jean-Richard Neeser
-
Publication number: 20030175957Abstract: This invention relates to new immortalized human pre-adipose cell lines capable of differentiating into adipose cells and methods of obtaing the immortalized cells. In particular, the present invention pertains to immortalized pre-adipocyte cell lines derived from white adipose tissue and methods of producing the cell lines. The immortalized pre-adipocyte cells are capable of maturing into immortalized white adipose cells useful in developing drugs, food ingredients and supplements against obesity, diabetes and cardiovascular diseases.Type: ApplicationFiled: January 21, 2003Publication date: September 18, 2003Applicant: NESTEC S.A.Inventors: Christian Darimont, Katherine Mace, Andrea Pfeifer
-
Publication number: 20030004095Abstract: A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.Type: ApplicationFiled: May 21, 2002Publication date: January 2, 2003Inventors: Raylene Alison Reimer, Christian Darimont-Nicolau, Katherine Mace, Sandrine Gremlich, Jean-Richard Neeser